[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
June 20, 2007

Chronic Kidney Disease and the Public HealthGaps in Evidence From Interventional Trials

Author Affiliations
 

Author Affiliation: Maine Medical Center, Portland.

JAMA. 2007;297(23):2630-2633. doi:10.1001/jama.297.23.2630

In recent years, chronic kidney disease has received increased attention as a leading public health problem.1 The kidney disease burden, measured in terms of prevalence, associated economic costs, and morbidity, is substantial and increasing. In the United States, more than 400 000 individuals have end-stage renal disease (ESRD),2 for which life can be sustained only with renal replacement therapy such as dialysis or kidney transplantation. In a recent population-based study of US residents 45 years and older, 9.5% had a first-degree relative with ESRD.3 It is estimated that by 2015, more than 700 000 individuals in the United States will have ESRD, and more than 107 000 ESRD-related deaths will occur annually.2 Cardiovascular mortality in patients with ESRD is 10- to 20-fold higher than in the general population and is the leading cause of death.4 Mortality rates for patients with ESRD have shown only modest improvement over the past 2 decades.

First Page Preview View Large
First page PDF preview
First page PDF preview
×